Stockscreener 앱 받기
462.13
1.15%
5.26
시간 외 거래:
462.13
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
How Will VRTX Stock React To Its Upcoming Earnings? - Forbes
Vertex's High-Volume Surge to $857M Ranks 141st Amid Mixed Analysts and Earnings Volatility - AInvest
Vertex Pharmaceuticals Secures $1B Financing on Boston HQ with 20-Year Lease Commitment - Stock Titan
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today - Benzinga
How To Trade Vertex Pharmaceuticals Stock Ahead of Its Upcoming Earnings? - Trefis
What makes Vertex Pharmaceuticals Incorporated stock price move sharplySwing Trade Target Finder With Low Risk - jammulinksnews.com
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - The Motley Fool
Stock Analysis | Vertex Pharmaceuticals OutlookA Cautious Technical Outlook Amid Mixed Analyst and Market Signals - AInvest
5 for Good: Vertex's paid internship benefits Boston students - WCVB
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Volume Surge May Signal Institutional Interest in Vertex Pharmaceuticals IncorporatedStable Entry High Return Opportunities in Focus - metal.it
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards? - TradingView
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals' (VRTX) Upcoming Earnings and Strategic Momentum: A Deep Dive into Long-Term Growth Potential Amid Pipeline Advancements and Financial Resilience - AInvest
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
How does Vertex Pharmaceuticals Incorporated generate profit in a changing economyMaximize your gains with expert trading tips - jammulinksnews.com
What institutional investors are buying Vertex Pharmaceuticals Incorporated stockAI Powered Entry Points That Work - jammulinksnews.com
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment - MSN
The 3 Things That Matter for Vertex Pharmaceuticals Now - AOL.com
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Should I hold or sell Vertex Pharmaceuticals Incorporated stock in 2025Rapid growth opportunities - jammulinksnews.com
Why is Vertex Pharmaceuticals Incorporated stock attracting strong analyst attentionInvest confidently with real-time data - jammulinksnews.com
Published on: 2025-07-27 22:21:17 - jammulinksnews.com
Is Vertex Pharmaceuticals Incorporated a growth stock or a value stockSuperior portfolio returns - jammulinksnews.com
Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - MSN
Vertex Bets Big On Rare Diseases And Pain Medicine - Finimize
What drives Vertex Pharmaceuticals Incorporated stock priceHigh-octane financial growth - Autocar Professional
Can Vertex Pharmaceuticals Incorporated stock recover from recent declineFree Risk Assessment Services - jammulinksnews.com
Three Indian American-led firms among TIME100 Most Influential Companies - The American Bazaar
Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada - Yahoo Finance
What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Market Return Analysis - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail
Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve
Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Gets a Hold from Wells Fargo - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - Yahoo Finance
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
2.46%
0.70%
자본화:
|
볼륨(24시간):